WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 18.08.2018 at 9:00 AM CEST
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2011013668) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ISCHEMIC EVENTS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2011/013668 International Application No.: PCT/JP2010/062631
Publication Date: 03.02.2011 International Filing Date: 27.07.2010
IPC:
A61K 45/06 (2006.01) ,A61K 31/275 (2006.01) ,A61K 38/46 (2006.01) ,A61P 7/02 (2006.01) ,A61P 9/00 (2006.01) ,A61P 43/00 (2006.01)
Applicants: SHIMOHATA, Takayoshi[JP/JP]; JP (UsOnly)
LAWRENCE Kauvar[US/US]; US (UsOnly)
Niigata University[JP/JP]; 8050, Ikarashi 2-no-cho, Nishi-ku, Niigata-shi, Niigata 9502181, JP (AllExceptUS)
Inventors: SHIMOHATA, Takayoshi; JP
LAWRENCE Kauvar; US
Agent: HIROTA, Koichi; HIROTA, NAGARE & ASSOCIATES, 4th Floor, Shinjuku TR Bldg., 2-2-13, Yoyogi, Shibuya-ku, Tokyo 1510053, JP
Priority Data:
2009-17409827.07.2009JP
2009-17409927.07.2009JP
2010-12437431.05.2010JP
2010-12438231.05.2010JP
Title (EN) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ISCHEMIC EVENTS
(FR) COMPOSITION PHARMACEUTIQUE UTILISABLE DANS LE CADRE DU TRAITEMENT D'ÉVÉNEMENTS ISCHÉMIQUES
(JA) 虚血性イベントの治療用医薬品組成物
Abstract:
(EN) Disclosed is a therapeutic pharmaceutical composition comprising a thrombolytic agent and an inhibitor capable of inhibiting a signaling that is mediated by a receptor of a vascular endothelial growth factor (VEGF). The therapeutic pharmaceutical composition can be used for the treatment of severe ischemic events including cerebral infarction, cardiac infarction and pulmonary embolism.
(FR) La présente invention concerne une composition pharmaceutique thérapeutique comprenant un agent thrombolytique et un inhibiteur capable d'inhiber une signalisation à médiation par un récepteur d'un facteur de croissance de l'endothélium vasculaire (VEGF). Ladite composition pharmaceutique thérapeutique peut être utilisée pour le traitement d'événements ischémiques graves, dont l'infarctus cérébral, l'infarctus du myocarde et l'embolie pulmonaire.
(JA)  血栓溶解薬、及び、血管内皮増殖因子(VEGF)の受容体によって仲介されるシグナル伝達を阻害する阻害剤を含み、脳梗塞、心筋梗塞、及び肺塞栓症を含む重篤な虚血性イベントの治療に用いられる治療用医薬品組成物である。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)